Alzheimer Disease — An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Citation(s)
Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging. 2007 Apr;28(4):533-6. doi: 10.1016/j.neurobiolaging.2006.02.012. Epub 2006 Mar 29.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275-85. doi: 10.1001/jama.295.19.2275. Erratum In: JAMA. 2006 Jun 7;295(21):2482.
Bradshaw MJ, Mobley BC, Zwerner JP, Sriram S Autopsy-proven demyelination associated with infliximab treatment. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e205. doi: 10.1212/NXI.0000000000000205. eCollection 2016 Apr. No abstract available.
Branders S, Bernard G and Pereira A Leveraging historical data for high-dimensional regression adjustment, a machine learning approach. PSI annual conference, Amsterdam, 3 to 6 June 2018.
Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging. 2010 Nov;31(11):1877-84. doi: 10.1016/j.neurobiolaging.2008.10.012. Epub 2008 Dec 13.
Chou RC, Kane M, Ghimire S, Gautam S, Gui J Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. CNS Drugs. 2016 Nov;30(11):1111-1120. doi: 10.1007/s40263-016-0374-z.
Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev. 2012 Oct;64(4):1004-26. doi: 10.1124/pr.112.005850. Epub 2012 Sep 10.
Dickson DW The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997 Apr;56(4):321-39. doi: 10.1097/00005072-199704000-00001.
Jaeger, J H., Clint; Loft, Henrick; Lim, Yen Ying; Aschenbrenner, Andrew; Segerdahl, Marta; Tong, Gary; Mielke, Michelle; Hassenstab, Jason; Stricker, Nikki (2017). The Early AD/ MCI Alzheimer's Cognitive Composite (EMACC): Development & preliminary validation across 4 longitudinal cohorts of a cognitive endpoint for clinical trials in MCI & Early AD stage disease. CTAD.
Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, Shen Y Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol Neurodegener. 2011 Oct 6;6:69. doi: 10.1186/1750-1326-6-69.
Kiresuk TJ, Sherman RE Goal attainment scaling: A general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968 Dec;4(6):443-53. doi: 10.1007/BF01530764.
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013 Feb;9(2):106-18. doi: 10.1038/nrneurol.2012.263. Epub 2013 Jan 8. Erratum In: Nat Rev Neurol. 2013. doi: 10.1038/nmeurol.2013.32. Liu, Chia-Chan [corrected to Liu, Chia-Chen].
Lutshumba J, Nikolajczyk BS, Bachstetter AD Dysregulation of Systemic Immunity in Aging and Dementia. Front Cell Neurosci. 2021 Jun 22;15:652111. doi: 10.3389/fncel.2021.652111. eCollection 2021.
MacPherson KP, Sompol P, Kannarkat GT, Chang J, Sniffen L, Wildner ME, Norris CM, Tansey MG Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol Dis. 2017 Jun;102:81-95. doi: 10.1016/j.nbd.2017.02.010. Epub 2017 Feb 24.
Pegoretti V, Baron W, Laman JD, Eisel ULM Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment. Front Immunol. 2018 Apr 30;9:925. doi: 10.3389/fimmu.2018.00925. eCollection 2018.
Probert L TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015 Aug 27;302:2-22. doi: 10.1016/j.neuroscience.2015.06.038. Epub 2015 Jun 24.
Siegel CA, Melmed GY Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol. 2009 Jul;2(4):245-51. doi: 10.1177/1756283X09336364.
Tarkowski E, Andreasen N, Tarkowski A, Blennow K Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200.
Valcarce C, Dunn I, and Burstein A Inflammatory Biomarkers, Brain Volumetric MRI, FDG-PET Results in Patients with Type 2 Diabetes in Azeligagonphase 3 Trial in Mild Alzheimer's Disease (AD).http://vtvtherapeutics.com/wp-content/uploads/2019/03/AD_PD-presentation_FINAL-March-30-2019_lisbon.pdf
Zhao A, Li Y, Deng Y; Alzheimer's Disease Neuroimaging Initiative TNF receptors are associated with tau pathology and conversion to Alzheimer's dementia in subjects with mild cognitive impairment. Neurosci Lett. 2020 Nov 1;738:135392. doi: 10.1016/j.neulet.2020.135392. Epub 2020 Sep 15.
Zhou M, Xu R, Kaelber DC, Gurney ME Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. PLoS One. 2020 Mar 23;15(3):e0229819. doi: 10.1371/journal.pone.0229819. eCollection 2020.
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.